Awaiting development: Guidance and quality standards

Showing 11 to 20 of 177

Guidance and quality standards awaiting development
Title	Type
Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]	Technology appraisal guidance
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]	Technology appraisal guidance
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis [ID4011]	Technology appraisal guidance
Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]	Technology appraisal guidance